Folgen
Sole Gatto
Sole Gatto
Bioinformatics Scientist
Bestätigte E-Mail-Adresse bei monocerosbio.com
Titel
Zitiert von
Zitiert von
Jahr
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ...
Cancer discovery 10 (1), 54-71, 2020
9642020
STAT3 signaling controls satellite cell expansion and skeletal muscle repair
MT Tierney, T Aydogdu, D Sala, B Malecova, S Gatto, PL Puri, L Latella, ...
Nature medicine 20 (10), 1182-1186, 2014
3802014
Denervation-activated STAT3–IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis
L Madaro, M Passafaro, D Sala, U Etxaniz, F Lugarini, D Proietti, ...
Nature cell biology 20 (8), 917-927, 2018
2242018
The KRAS (G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020; 10: 54–71. doi …
J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ...
Nat Can 1 (1), 25-7, 2020
1842020
Dynamics of cellular states of fibro-adipogenic progenitors during myogenesis and muscular dystrophy
B Malecova, S Gatto, U Etxaniz, M Passafaro, A Cortez, C Nicoletti, ...
Nature communications 9 (1), 3670, 2018
1602018
Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease
EC Lee, T Valencia, C Allerson, A Schairer, A Flaten, M Yheskel, ...
Nature communications 10 (1), 4148, 2019
1092019
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
DM Briere, S Li, A Calinisan, N Sudhakar, R Aranda, L Hargis, DH Peng, ...
Molecular cancer therapeutics 20 (6), 975-985, 2021
872021
Whole-genome bisulfite DNA sequencing of a DNMT3B mutant patient
H Heyn, E Vidal, S Sayols, JV Sanchez-Mut, S Moran, I Medina, ...
Epigenetics 7 (6), 542-550, 2012
842012
Transcription factor-directed re-wiring of chromatin architecture for somatic cell nuclear reprogramming toward trans-differentiation
A Dall’Agnese, L Caputo, C Nicoletti, J di Iulio, A Schmitt, S Gatto, Y Diao, ...
Molecular cell 76 (3), 453-472. e8, 2019
702019
ICF-specific DNMT3B dysfunction interferes with intragenic regulation of mRNA transcription and alternative splicing
S Gatto, M Gagliardi, M Franzese, S Leppert, M Papa, M Cammisa, ...
Nucleic acids research 45 (10), 5739-5756, 2017
552017
Comprehensive RNA-sequencing analysis in serum and muscle reveals novel small RNA signatures with biomarker potential for DMD
AML Coenen-Stass, H Sork, S Gatto, C Godfrey, A Bhomra, K Krjutškov, ...
Molecular Therapy-Nucleic Acids 13, 1-15, 2018
442018
Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome
S Gatto, F Della Ragione, A Cimmino, M Strazzullo, M Fabbri, M Mutarelli, ...
Epigenetics 5 (5), 427-443, 2010
412010
Genome-wide DNA methylation analysis identifies novel hypomethylated non-pericentromeric genes with potential clinical implications in ICF syndrome
L Simo-Riudalbas, A Diaz-Lagares, S Gatto, M Gagliardi, AB Crujeiras, ...
PloS one 10 (7), e0132517, 2015
372015
TBP/TFIID-dependent activation of MyoD target genes in skeletal muscle cells
B Malecova, A Dall'Agnese, L Madaro, S Gatto, P Coutinho Toto, S Albini, ...
eLife, 2016
272016
Variegated silencing through epigenetic modifications of a large Xq region in a case of balanced X; 2 translocation with Incontinentia Pigmenti-like phenotype
R Genesio, D Melis, S Gatto, A Izzo, V Ronga, G Cappuccio, A Lanzo, ...
Epigenetics 6 (10), 1242-1247, 2011
142011
Muscle-relevant genes marked by stable H3K4me2/3 profiles and enriched MyoD binding during myogenic differentiation
H Cui, V Bansal, M Grunert, B Malecova, A Dall'Agnese, L Latella, S Gatto, ...
PloS one 12 (6), e0179464, 2017
132017
Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination …
DM Briere, A Calinisan, R Aranda, N Sudhakar, L Hargis, S Gatto, ...
Molecular Cancer Therapeutics 18 (12_Supplement), LB-C09-LB-C09, 2019
112019
The KRAS (G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic …
DM Briere, A Calinisan, R Aranda, N Sudhakar, L Hargis, S Gatto, ...
MOLECULAR CANCER THERAPEUTICS 18 (12), 2019
82019
Single Cell Gene Expression Profiling of Skeletal Muscle-Derived Cells
S Gatto, PL Puri, B Malecova
Muscle Stem Cells 1556, 191-219, 2017
82017
The Role of DNMT3B Mutations in the Pathogenesis of ICF Syndrome
S Gatto, M D’Esposito, MR Matarazzo
Patho-Epigenetics of Disease, 15-41, 2012
62012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20